Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Sarcoma 1CNS 1

Conditions

Proliferative Breast Disease 1Oligodendroglioma 1Neoplasm Metastasis 1Gliosarcoma 1Glioblastoma 1Ependymoma 1Childhood Brain Neoplasm 1Carcinoma, Renal Cell 1Brain Neoplasms 1Astrocytoma 1

Interventions

Magnetic Resonance Spectroscopy 6Temozolomide 3Biopsy 3Bevacizumab 3posaconazole 2fluciclovine F-18 2Topotecan 2Specimen Handling 2Radiosurgery 2Pemetrexed 2Nivolumab 2Methotrexate 2Ketoconazole 2Fluorodeoxyglucose F18 2ribociclib 1relatlimab 1mycophenolic adenine dinucleotide 1montelukast 1gancotamab 1fluoromisonidazole 1fluorodopa F 18 1fludarabine phosphate 1etoposide phosphate 1eribulin 1dexamethasone acetate 1dexamethasone 21-phosphate 1clevudine 1ceritinib 1brivaracetam 1auricularum 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase EARLY_PHASE1 × Brain Neoplasms × Dynamic Contrast Enhanced Magnetic Resonance Imaging × Clear all
NCT01996527 2017-04-17

3T MRI Biomarkers of Glioma Treatment Response

Vanderbilt-Ingram Cancer Center

Phase EARLY_PHASE1 Terminated
7 enrolled
CNSSarcoma

Astrocytoma, Brain Neoplasms, Ependymoma, Glioblastoma, Oligodendroglioma, Gliosarcoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡